Groundbreaking insights from the 9th Cardiovascular Outcome Trial (CVOT) Summit

Illustration of a human heart

Don’t miss out on groundbreaking insights from the 9th Cardiovascular Outcome Trial (CVOT) Summit! Our Chief Medical Officer, Thomas Forst, Prof. Dr., collaborated with global leaders in endocrinology, cardiology, diabetology, nephrology, and more to discuss recent trial outcomes. This virtual summit showcased advancements in cardiovascular risk reduction, metabolic outcomes improvement, and obesity-related heart failure treatment. Moreover, […]

New Study: „Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: Impact on pharmacokinetics and drug-drug interactions“

medical illustration of a human liver

Ever wondered how chronic liver diseases impact medication effectiveness? The study „Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: Impact on pharmacokinetics and drug-drug interactions“ conducted by Dr. Sara Armani and Thomas Forst, Prof. Dr. (in collaboration with our partners from around the world) delves into this crucial topic. Their […]

Critical insights: Atrogi Announces Positive Clinical Data from First-in-Class Insulin-Independent Treatment for Type 2 Diabetes

Mannheim, Germany, March 18th 2024 –  Atrogi, a pioneering clinical-stage biotech company advancing treatments for metabolic disorders, announces the full set of results from its Phase 1 a/b trial with ATR-258, its first-in-class treatment for type 2 diabetes (T2D). This clinical trial, conducted on both healthy volunteers and individuals with T2D, underscores the safety of ATR-258 […]